King's College London

Research portal

‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine

Research output: Contribution to journalReview article

Silvia Rota, Iro Boura, Lucia Batzu, Nataliya Titova, Peter Jenner, Cristian Falup-Pecurariu, K. Ray Chaudhuri

Original languageEnglish
Pages (from-to)953-965
Number of pages13
JournalExpert Review of Neurotherapeutics
Volume20
Issue number9
DOIs
Accepted/In press1 Jan 2020
Published1 Sep 2020

King's Authors

Abstract

Introduction: Dopamine agonists have been widely used to treat patients with Parkinson’s disease, but concerns related to their well-known side effects might prevent their use even when indicated. In this review, the authors describe for the first time the concept of ‘Dopamine Agonist Phobia’, a pharmacophobia that the authors believe might affect clinicians, and they provide evidence of the benefits of dopamine agonists, focusing on non-motor symptoms. Areas covered: The authors performed an extensive literature research, including studies exploring the use of dopamine agonists for the treatment of non-motor symptoms. The authors indicate the highest level of evidence in each section. Expert opinion: ‘Dopamine Agonist Phobia’ may preclude valid therapeutic options in selected cases, specifically for the treatment of non-motor symptoms. Thus, the authors propose a personalized approach in Parkinson’s disease treatment, and encourage a thoughtful use of dopamine agonists, rather than an overall nihilism.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454